Part 2: Importance and Implications of Biomarkers in Diagnosis and Modern Treatment of Alzheimer’s Disease
Not only are cases of mild cognitive impairment (MCI) often not diagnosed, but more than 50% of these patients are misdiagnosed.
Category
Format
Credits
Part 3: Evolving Roles in Alzheimer’s Disease Management: Team-Based Care in the Modern Age of Disease-Modifying Therapy
Due to the growing complexity in the management of Alzheimer’s disease (AD), patient care falls under a wide umbrella of clinical team members across specialties, increasing the complexity of disease management.
Category
Format
Credits
Battle of the Biomarkers: Assessing Key Factors in Prognosis, Monitoring, and Therapeutic Decision-Making for Disease Worsening in Multiple Sclerosis
OverviewOver the past several years, the image of MS has been changing from distinct categories of disease to a complicated spectrum of interwoven pathologies. As this knowledge evolves, so do approaches to prognosticating, monitoring, and responding to disease.
Category
Format
Credits
A Deeper Look at Neuromyelitis Optica Spectrum Disorder: A Glimpse Onto the Clinic Floor with Specialists
OverviewThough neuromyelitis optica spectrum disorder (NMOSD) has had a specific lab marker (AQP4 antibody) for many years, its relapsing nature and overlapping syndromes still causes it to be confused with multiple conditions such as multiple sclerosis (MS), leading to inappropriate and
Category
Format
Credits
Stronger Together: Leveraging Evidence-Based Patient Collaboration and Treatment Strategies to Streamline Success in Multiple Sclerosis
Program DescriptionWith the variety of possible risk factors, presentations, impacts, and preferences among individual patients with multiple sclerosis (MS), it has been well-established that every case of MS is unique.
Category
Format
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Unlocking the Alzheimer’s Brain: How Radiological Tools and Biomarkers Hold the Key to Early Diagnosis and Decision-Making
Program DescriptionThe age of disease-modifying therapy in Alzheimer’s disease (AD) is now a reality with one amyloid beta targeting therapy (ATT) approved and another under regulatory review.
Category
Format
Credits
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
The Frontline of Alzheimer's Care: Addressing Real Questions from Clinicians in the New Dawn of Disease-Modifying Therapy
Due to the unique educational design of this course, the content must be viewed and completed on the ReachMD 
Category
Format
Credits
On the Clinic Floor: Addressing the Most Critical Questions of Frontline Clinicians in Multiple Sclerosis Management
Due to the unique educational design of this course, the content must be viewed and completed on the ReachMD plat
Category
Format
Credits
When the Default is Not Enough: An Emergency Medicine Clinician's Guide to Novel Amyloid-Related Imaging Abnormalities in Alzheimer's Disease
 
Category
Format
Credits
  • 1.00 AAPA Category I CME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Pay It Forward: Bridging the Gaps Between Payers and Providers to Get the Medication Your Patient Needs When They Need It for Narcolepsy and Idiopathic Hypersomnia
Program DescriptionPatients with narcolepsy type 1 (NT-1), narcolepsy type 2 (NT-2), and idiopathic hypersomnia (IH) have a diverse range of clinical presentations and therapeutic needs that complicate the process of diagnosis and management.
Category
Format
Credits
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Attendance

Pages